Showing results (171-180 of 326) with videos related to
Sort By:
Pageof 33
British Journal of Haematology|April 15, 2025
Enhancing risk stratification and treatment decision in multiple myeloma with SKY92 gene expression profiling in real-world dataNoa Biran, Binod Dhakal, Ruben Niesvizky, et al.Journal of Comparative Effectiveness Research|April 28, 2023
Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myelomaAmrita Krishnan, Ajay K Nooka, Ajai Chari, et al.Current Medical Research and Opinion|October 22, 2022
Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myelomaTom Martin, Saad Z Usmani, Jordan M Schecter, et al.Hematological Oncology|February 14, 2020
Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myelomaAjai Chari, Robert F Cornell, Cristina Gasparetto, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 24, 2018
Higher Incidence of Hemorrhagic Cystitis Following Haploidentical Related Donor Transplantation Compared with Matched Related Donor TransplantationOlivia R Copelan, Srinivasa R Sanikommu, Jigar S Trivedi, et al.Blood Advances|November 4, 2022
Waldenström macroglobulinemia whole genome reveals prolonged germinal center activity and late copy number aberrationsKylee H Maclachlan, Tina Bagratuni, Efstathios Kastritis, et al.Journal of Athletic Training|December 1, 2025
Comparison of Gluteus Medius Muscle Activation in Women With and Without Patellofemoral PainMichelle N Samuel, Szu-Ping Lee, Andrew Hooyman, et al.The Lancet. Oncology|December 6, 2021
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 studySaad Z Usmani, Hang Quach, Maria-Victoria Mateos, et al.The Lancet. Haematology|December 28, 2020
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trialSaad Z Usmani, Antje Hoering, Sikander Ailawadhi, et al.Blood Cancer Journal|November 25, 2018
Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research ProjectSaad Z Usmani, Antje Hoering, Michele Cavo, et al.Pageof 33